Rapport Therapeutics, Inc. RAPP Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Rapport Therapeutics, Inc. (RAPP) reported accretion (amortization) of discounts and premiums, investments of $364K in Q1 2026.
- How has Rapport Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Rapport Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 16.5% year-over-year, from $436K to $364K.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or accretion of discounts on investment securities. This adjustment reconciles the difference between the purchase price of an investment and its face value over the holding period. It is essential for understanding the true yield generated by the company's investment portfolio.